← Back to patent-cliff list
CAS 1464999-05-0
4-(5-(bis(2-hydroxyethyl)amino)-2-hydroxy-1-methyl-2,3-dihydro-1H-benzo[d]imidazol-2-yl)butanoic acid
Codes: BENDAM-021
Application context (from source-drug indications)
B-cell lymphomaBendamustine HydrochlorideNon-Hodgkin lymphomaBendamustine HydrochlorideChronic lymphocytic leukaemiaBendamustine HydrochlorideMantle cell lymphomaBendamustine HydrochlorideLymphomaBendamustine HydrochlorideMultiple myelomaBendamustine Hydrochloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Bendamustine Hydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
dihydro-2H-pyran-2,6(3H)-dione→2,2'-((4-fluoro-3-nitrophenyl)azanediyl)bis(ethan-1-ol)→2,2'-((4-(methylamino)-3-nitrophenyl)azanediyl)bis(ethan-1-ol)→2,2'-((3-amino-4-(methylamino)phenyl)azanediyl)bis(ethan-1-ol)→4-(5-(bis(2-hydroxyethyl)amino)-2-hydroxy-1-methyl-2,3-dihydro-1H-benzo[d]imidazol-2-yl)butanoic acid→methyl 4-(5-(bis(2-hydroxyethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.